$AMBS Business Summary

Amarantus BioScience, Inc., a development-stage biotechnology company, focuses on the discovery and development of therapeutic proteins and biologics for the treatment of Parkinson?s disease, traumatic brain injury (TBI), and other human diseases in the United States. The company owns the intellectual property rights to a therapeutic protein, known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF), which corrects protein misfolding. It is developing the MANF Program to disease-modifying treatments for Parkinson?s disease, as well as for other apoptosis-related disorders. The company also has a collaboration agreement with Banyan Biomarkers for the treatment of TBI based on its MANF proprietary anti-apoptotic therapeutic protein. In addition, it owns an inventory of 88 cell lines referred to as PhenoGuard Cell Lines. The company was formerly known as Amarantus BioSciences, Inc. and changed its name to Amarantus BioScience, Inc. in December 2012. Amarantus BioScience, Inc. was founded in 2008 and is based in Sunnyvale, California.